The issued US patent extends the intellectual property surrounding the company’s franchise of oral gallium-containing products that are intended as potential treatment for diseases associated with accelerated bone loss.
The lead compound in this investigational pipeline, G4544, was developed in collaboration with Emisphere Technologies, and has completed its initial Phase I dose-ranging study.